Anaheim, California (September 6, 2011) – Anaheim Clinical Trials (ACT), an adult and pediatric Phase I-IV clinical research center with full-service CRO capabilities located in southern California, today announced their executed License Agreement with ClinicalRSVP.com, the nationwide network that prevents research volunteers from enrolling in multiple concurrent research studies. This agreement allows ACT to confidentially and securely verify subject eligibility requirements prior to study enrollment.
ACT joins a multitude of sites throughout North America using the subject registry to bring about advances to data integrity and cost savings for study sponsors. By joining the ClinicalRSVP.com network, ACT anticipates direct benefits for their study sponsors including the following:
- More reliable, protocol compliant study data
- Better adherence to clinical development timelines
- Increased participant safety
- Minimized risk of unwarranted adverse events due to overlapping subject participation
- Increased Screening Accuracy
ACT’s Medical Director, Dr. Peter Winkle, M.D., F.A.C.G, F.A.C.P., C.P.I., states “Dual subject enrollment in clinical research trials has been an industry concern for some time. Now that a remedy to stop dual enrollment is available with a fair and balanced approach, ACT is pleased to join with other dedicated sites to ensure the safety and integrity of our studies.”
The President of ClinicalRSVP.com, Darran Boyer added “We are thrilled for the opportunity to provide this valuable service to ACT, and are excited by the additional coverage their site will be contributing to the overall ClinicalRSVP network. It is through the dedicated efforts of sites such as ACT that advances to clinical research are made possible.”
About Anaheim Clinical Trials
Anaheim Clinical Trials (ACT) is an adult and pediatric Phase I-IV clinical research center with full-service CRO capabilities, located in southern California (Anaheim). In addition to healthy volunteers, ACT has been particularly successful in enrolling special patient populations, such as renal- and hepatic-impaired patients, and Japanese subjects for ethno-bridging trials. Our certified Principal Investigators have the expertise and interest in a wide variety of therapeutic areas, including GI, pain, metabolic/inflammation, infectious disease, and respiratory. ACT has been recognized by our customers for excellent quality research, timeliness, high patient enrollment, and ease of doing business. For more information, please visit our website at www.anaheimclinicaltrials.com.
ClinicalRSVP the nationwide network that prevents research volunteers from enrolling in multiple concurrent research studies. This blinded cooperative registry allows investigators to confidentially and securely verify subject eligibility requirements prior to subject enrollment in clinical trials, resulting in advances to clinical research data integrity and participant safety. For more information about ClinicalRSVP, visit www.clinicalrsvp.com.
FOR IMMEDIATE RELEASE
Linda Gundaker, MBA, MT(ASCP)
Anaheim Clinical Trials (ACT)